Key result
NS-089/NCNP-02, an antisense oligonucleotide with a novel connected-sequence design, induced exon 44 skipping in vitro in patient-derived cells and in vivo in skeletal and cardiac muscle of cynomolgus monkeys.
Why the study?
Existing antisense oligonucleotides for exon skipping target a single continuous sequence, prompting investigation of a novel connected-sequence design to improve exon 44 skipping activity in Duchenne muscular dystrophy.
NS-089/NCNP-02, an antisense oligonucleotide with a novel connected-sequence design, successfully induced exon 44 skipping in vitro and in vivo, including in cardiac muscle, supporting its potential as a therapy for Duchenne muscular dystrophy.
Answers are grounded in this paper and cite their sources.
Supports exon 44 skipping in primate cardiac muscle; leaves open human translation and clinical efficacy.
Exon-skipping therapy mediated by antisense oligonucleotides (ASOs) is expected to provide a therapeutic option for Duchenne muscular dystrophy (DMD). ASOs for exon skipping reported so far target a single continuous sequence in or around the target exon. In the present study, we investigated ASOs for exon 44 skipping (applicable to approximately 6% of all DMD patients) to improve activity by using a novel ASO design incorporating two connected sequences. Phosphorodiamidate morpholino oligomers targeting two separate sequences in exon 44 were created to simultaneously target two splicing regulators in exon 44, and their exon 44 skipping was measured. NS-089/NCNP-02 showed the highest skipping activity among the oligomers. NS-089/NCNP-02 also induced exon 44 skipping and dystrophin protein expression in cells from a DMD patient to whom exon 44 skipping is applicable. We also assessed the in vivo activity of NS-089/NCNP-02 by intravenous administration to cynomolgus monkeys. NS-089/NCNP-02 induced exon 44 skipping in skeletal and cardiac muscle of cynomolgus monkeys. In conclusion, NS-089/NCNP-02, an ASO with a novel connected-sequence design, showed both in vitro and in vivo exon-skipping activity.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2023) studied Duchenne muscular dystrophy. NS-089/NCNP-02 vs. Vehicle (0 mg/kg) was evaluated on Exon 44 skipping efficiency in skeletal muscle (gastrocnemius) of cynomolgus monkeys. NS-089/NCNP-02, an antisense oligonucleotide with a novel connected-sequence design, induced exon 44 skipping in vitro in patient-derived cells and in vivo in skeletal and cardiac muscle of cynomolgus monkeys.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: